Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL [Phase 3]
Phase 3 trial comparing rituximab biosimilar HLX01 plus CHOP versus rituximab with CHOP in previously untreated CD20+ diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations [Phase 2]
Phase 2 trial evaluating CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including MYC-altered cases, has completed with resu…
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update investigating toripalimab in combination with rituximab followed by R-CHOP for elderly patients with untreated diffuse…
-
CLINICAL_TRIALS trial_result · 2022-04-11Clinical Trial Update: A Phase I Trial of AZD3965 in Patients With Advanced Cancer [Phase 1]
Phase I trial of AZD3965 in adults with advanced cancer, including diffuse large B-cell lymphoma and Burkitt lymphoma, completed with result…
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) [Phase 2]
Phase 2 clinical trial evaluating anti-PD-1 antibody with chidamide and rituximab in relapsed or refractory diffuse large B-cell lymphoma (D…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL [Phase 2]
Phase 2 trial evaluating camrelizumab plus R-CHOP in untreated primary extranodal diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2022-04-01Clinical Trial Update: Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL [Phase 2]
Phase 2 trial evaluating pre-phase treatment before R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: ZR-CHOP in DLBCL With Specific Gene Abnormality [Phase 2]
Phase 2 trial update of ZR-CHOP in diffuse large B-cell lymphoma with a specific gene abnormality.
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma [Phase 2]
Phase II study evaluating zanubrutinib with lenalidomide and R-CHOP as first-line therapy for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-03-07Clinical Trial Update: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL [Phase 2]
Phase 2 trial investigating penpulimab with R2-GemOx regimen for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients [Phase 2]
Phase 2 trial comparing R-CHOP14 vs R-CHOP21 with consolidation PET-oriented radiotherapy in diffuse large B-cell lymphoma (DLBCL) has compl…
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) [Phase 1]
Phase 1 study evaluating the safety and preliminary efficacy of the combination of blinatumomab and pembrolizumab in adults with relapsed or…
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL [Phase 2]
A Phase 2 trial evaluating the combination of obinutuzumab and venetoclax in relapsed or refractory diffuse large B-cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating ibrutinib with lenalidomide and rituximab in relapsed or refractory diffuse large B-cell lymphoma has completed w…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma [Phase 2]
Phase 2 protocol update for DLCL002 in high-risk aggressive B-cell lymphoma patients.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. [Phase 3]
Phase 3 trial comparing Zevalin regimen versus no further treatment in diffuse large B-cell lymphoma was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL [Phase 2]
Phase II clinical trial investigating the efficacy and safety of F520 in combination with F007 for relapsed/refractory diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects [Phase 2]
Phase 2 clinical trial update evaluating Chi-BEAC with auto-HSCT for aggressive lymphomas, reporting on efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2021-12-27Clinical Trial Update: Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients [Phase 2]
Phase 2 trial update evaluating ofatumumab with IVAC salvage chemotherapy in patients with diffuse large B cell lymphoma (DLBCL) that has re…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 clinical trial update investigating zanubrutinib with rituximab and/or combination chemotherapy for newly diagnosed aggressive B-cel…
-
CLINICAL_TRIALS trial_result · 2021-12-16Clinical Trial Update: Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy [Phase 3]
Phase 3 trial evaluating Zevalin vs observation in older patients with newly diagnosed DLBCL achieving PET-negative complete remission after…
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity [Phase 2]
Phase 2 safety and efficacy study of Defibrotide for preventing CAR-T cell–associated neurotoxicity in patients with DLBCL; study TERMINATED…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating a combination of chemotherapy, rituximab, and ixazomib citrate in adults with various aggressive B-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 trial evaluating axicabtagene ciloleucel (KTE-C19) for adults with refractory or relapse…
-
CLINICAL_TRIALS trial_result · 2021-11-22Clinical Trial Update: PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT [Phase 3]
Phase 3 trial evaluating maintenance therapy with the PD-1 inhibitor tislelizumab in newly diagnosed diffuse large B-cell lymphoma patients …